Esperion Therapeutics, Inc.

ESPRDelisted Jul 13, 2026

Industry: Pharmaceutical Preparations
SEC CIK: 0001434868

SEC filings (opens in a new tab)

Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.

Q2 2022 vs. Q1 2022

How the institutions holding Esperion Therapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022 All holders in Q1 2022

13F holders of ESPR: Q1 2022 compared with Q2 2022
Measure	Q1 2022	Of which not filed for Q2 2022	Q2 2022	Change
Holders	132	2	137	+7
Shares	51.9M	177.7K	55.3M	+3.57M (+6.9%)
Value	$241.2M	$825.0K	$352.1M	+$111.7M (+46.5%)

2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (24)

Institutions that held Esperion Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to ESPR in Q2 2022
Institution	Shares	Value	% of portfolio
Ikarian Capital, LLC	2,054,602	$13.1M	5.42%
Point72 Asset Management, L.P.	1,063,096	$6.76M	0.03%
Woodline Partners LP	844,635	$5.37M	0.09%
Boothbay Fund Management, LLC	271,543	$1.73M	0.06%
Pura Vida Investments, LLC	212,123	$1.35M	0.21%
SG Americas Securities, LLC	61,583	$392.0K	0.01%
Squarepoint Ops LLC	48,065	$306.0K	0.00%
HRT Financial LP	33,466	$212.0K	0.00%
Marshall Wace, LLP	26,600	$169.0K	0.00%
Jane Street Group, LLC	25,388	$161.0K	0.00%
Panagora Asset Management Inc	20,671	$131.0K	0.00%
Caxton Associates LP	19,768	$126.0K	0.02%
Mirae Asset Global Investments Co., Ltd.	18,019	$114.0K	0.00%
Verition Fund Management LLC	16,800	$107.0K	0.00%
Two Sigma Advisers, LP	13,400	$85.0K	0.00%
Caption Management, LLC	12,300	$78.0K	0.01%
Balyasny Asset Management LLC	11,971	$76.0K	0.00%
Raymond James & Associates	10,840	$69.0K	0.00%
Venture Visionary Partners LLC	7,830	$49.8K	0.00%
Aquatic Capital Management LLC	3,600	$23.0K	0.01%
Private Trust Co NA	400	$3.00K	0.00%
Trust Co of Vermont	300	$2.00K	0.00%
Dark Forest Capital Management LP	82	$1.00K	0.00%
Parallel Advisors, LLC	35	$0	0.00%

Sold out (17)

Institutions that held Esperion Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of ESPR in Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
Swedbank AB	217,000	$1.01M
Pictet Asset Management SA	191,547	$889.0K
Susquehanna International Group, LLP	97,136	$451.0K
Kestra Advisory Services, LLC	41,570	$193.0K
AQR Capital Management LLC	41,059	$191.0K
Bayesian Capital Management, LP	29,795	$138.0K
XTX Topco Ltd	18,686	$87.0K
Telemetry Investments, L.L.C.	17,500	$81.0K
Dynamic Technology Lab Private Ltd	15,598	$72.0K
State of Wyoming	10,894	$51.0K
Denali Advisors LLC	10,500	$49.0K
NewSquare Capital LLC	1,600	$7.00K
Bollard Group LLC	1,121	$5.00K
Creative Financial Designs Inc	275	$1.00K
Prospera Financial Services Inc	203	$1.00K
The PNC Financial Services Group, Inc.	35	$0
AdvisorNet Financial, Inc	95	$0

Not filed for Q2 2022 yet (2)

Institutions that held Esperion Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ESPR in Q1 2022 that haven't filed for Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
Parametric Portfolio Associates LLC	170,404	$791.0K
Amalgamated Financial Corp.	7,266	$34.0K